An error occurred retrieving publication content to display, please try again.
Home >> Journals >> Health Technology Assessment >> Page Not FoundPlease choose a page from the navigation or try a website search above to find the information you need.
Study finds that naftidrofuryl oxalate and cilostazol both appear to be effective treatments for adults presenting with intermittent claudication due to peripheral arterial disease with few serious adverse events; however, only naftidrofuryl oxalate is estimated to have an incremental cost per QALY gained below £20,000
{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}
H Squires, E Simpson, Y Meng, S Harnan, JW Stevens, R Wong, S Thomas, J Michaels & G Stansby.
H Squires *, E Simpson, Y Meng, S Harnan, JW Stevens, R Wong, S Thomas, J Michaels, G Stansby
School of Health and Related Research (ScHARR) Technology Assessment Group, University of Sheffield, Sheffield, UK
* Corresponding author Email: h.squires@sheffield.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
[Image - Crossmark status check]The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
No responses have been published.
An error has occurred in processing the XML document
© NIHR 2024